Jump to:
Celadon Pharmaceuticals PLC Fundamentals
| Company Name | Celadon Pharmaceuticals PLC | Last Updated | 2024-10-02 |
|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
|---|
| Shares in Issue | 68.846 m | Market Cap | £18.59 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.12 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.5648 | Debt Equity Ratio | 1.9317 |
|---|
| Asset Equity Ratio | 3.4497 | Cash Equity Ratio | 0.0065 |
|---|
| Quick Ratio | 0.1014 | Current Ratio | 1.92 |
|---|
| Price To Book Value | 7.0822 | ROCE | 0 |
|---|
Celadon Pharmaceuticals PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Celadon Pharmaceuticals PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £6.17 m | £6.28 m | 0 |
| Intangible Assets | £328,000.00 | £428,000.00 | 0 |
| Investments | £218,000.00 | £218,000.00 | 0 |
| Total Fixed Assets | £6.72 m | £6.92 m | 0 |
| Stocks | £100,000.00 | £20,000.00 | 0 |
| Debtors | £75,000.00 | 0 | £2.13 m |
| Cash & Equivalents | £1.26 m | £5.06 m | £4.46 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £9.22 m | £13.25 m | £6.61 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £955,000.00 | £1.20 m | £176,929.00 |
| Creditors after 1 year | £5.08 m | £5.02 m | £20,300.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £6.04 m | £6.21 m | £197,229.00 |
| Net assets | £3.18 m | £7.04 m | £6.41 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £642,000.00 | £617,000.00 | £80,334.00 |
| Share Premium | £25.55 m | £22.60 m | £7.42 m |
| Profit / Loss | -£7.52 m | -£18.12 m | -£720,369.00 |
| Other Equity | £3.16 m | £7.67 m | £6.41 m |
| Preference & Minorities | £23,000.00 | -£638,000.00 | 0 |
| Total Capital Employed | £3.18 m | £7.04 m | £6.41 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | £0.60 | £0.37 | 0 |
| Debt-to-Equity | £1.47 | £0.59 | 0 |
| Assets / Equity | 3.4497 | 3.4497 | 3.4497 |
| Cash / Equity | 0.0065 | 0.0065 | 0.0065 |
| EPS | -£0.10 | -£0.28 | -£0.09 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£5.97 m | -£6.10 m | -£2.71 m |
| Cashflow before financing | -£3.46 m | -£152,000.00 | -£1.03 m |
| Increase in Cash | -£3.80 m | £1.24 m | -£1.03 m |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £75,000.00 | £24,000.00 | 0 |
| Cost of sales | 0 | £90,000.00 | £12,000.00 |
| Gross Profit | £75,000.00 | -£66,000.00 | -£10,000.00 |
| Operating Profit | -£5.93 m | -£5.38 m | -£722,384.00 |
| Pre-Tax profit | -£7.52 m | -£18.12 m | -£720,369.00 |
Celadon Pharmaceuticals PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis. It operates only in the UK and has only one geographical area. |
|---|
| Latest Interim Date | 30 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 14 May 2024 |
|---|
Celadon Pharmaceuticals PLC Directors
| Appointed | Name | Position |
|---|
| 2024-06-10 | Mr. David Samuel Peter Firth | Non-Executive Director |
| 2024-06-10 | Mr. Robert Nicholas Barr | Non-Executive Director,Senior Independent Non-Executive Director |
| 2024-06-10 | Mr. Jonathan Paul Turner | Executive Director,Chief Financial Officer |
| 2024-06-10 | Mr. James Gareth Short | Executive Director,Chief Executive Officer |
| 2024-06-10 | Mr. Alexander Anton | Non-Executive Director,Chairman |
Celadon Pharmaceuticals PLC Contact Details
Celadon Pharmaceuticals PLC Advisors
